Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**4-amino-1,8-naphthalimide** is a small molecule inhibitor of the enzyme poly(ADP-ribose) polymerase (PARP), with a reported IC50 of 180 nM[1][4]. PARP enzymes are nuclear proteins involved in DNA repair, apoptosis, and several cellular processes. 4-amino-1,8-naphthalimide is used mainly as a research tool rather than a therapeutic agent and is notable for its role in potentiating the cytotoxicity of gamma-radiation in cancer cells, serving as a radiation sensitizer without direct cytotoxicity in the absence of irradiation[1][4]. It is also a fluorescent compound, useful for cellular imaging and as a molecular probe in various chemical biology applications[3]. To date, 4-amino-1,8-naphthalimide is not approved for human therapeutic use but is widely used in laboratory studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-amino-1,8-naphthalimide.